Renovorx announces abstract presentation at the society of surgical oncology (sso) 2025

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing innovative targeted oncology therapies and commercializing renovocath®, a novel, fda-cleared drug-delivery device, is proud to announce a presentation of a new pre-clinical clinical data abstract at the upcoming society of surgical oncology (sso) 2025 annual meeting. the abstract, titled “pharmacodynamics of intra-arterial vs. intravenous gemcitabine in locally.
RNXT Ratings Summary
RNXT Quant Ranking